Department of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China.
Key Laboratory of Radiobiology, Ministry of health, School of Public Health, Jilin University, Changchun, 130021, China.
Stem Cell Res Ther. 2018 Jan 31;9(1):18. doi: 10.1186/s13287-018-0776-6.
Since radiotherapy is widely used in managing thoracic tumors, physicians have begun to realize that radiation-induced lung injury (RILI) seriously limits the effects of radiotherapy. Unfortunately, there are still no effective methods for controlling RILI. Over the last few decades numerous studies have reported the beneficial effects of mesenchymal stem cells (MSCs) on tissue repair and regeneration. MSCs can not only differentiate into lung alveolar epithelial cells and secrete anti-inflammatory factors, but they also deliver some vehicles for gene therapy in repairing the injured lung, which provides new ideas for managing RILI. Thus, many scientists have attempted to manage RILI using MSC-based therapy. However, as a novel therapy MSCs still face various limitations. Herein, we shed light on the current understanding of MSC-based therapy for RILI, including the feasibility, molecular mechanisms, animal studies, and clinical research of MSC-based therapy for RILI. We also present an overview of RILI and MSCs.
由于放射疗法在胸部肿瘤的治疗中得到广泛应用,医生们开始意识到放射性肺损伤(RILI)严重限制了放射疗法的效果。不幸的是,目前仍然没有控制 RILI 的有效方法。在过去几十年中,许多研究报告了间充质干细胞(MSCs)对组织修复和再生的有益作用。MSCs 不仅可以分化为肺泡上皮细胞并分泌抗炎因子,还可以在修复受损肺部时传递一些基因治疗载体,这为管理 RILI 提供了新的思路。因此,许多科学家试图使用基于 MSC 的疗法来管理 RILI。然而,作为一种新型疗法,MSCs 仍然面临着各种限制。在此,我们介绍了基于 MSC 的 RILI 治疗的最新研究进展,包括基于 MSC 的 RILI 治疗的可行性、分子机制、动物研究和临床研究。我们还对 RILI 和 MSCs 进行了概述。